Clients save average 20% on cancer claims; members have better treatment experience

Why Clients Choose ITA Partnersalt

  • Treatment plan review assures evidence-based treatment     is prescribed
  • Holistic review includes surgery, chemotherapy, radiation, supportive medications, diagnostics
  • Personalized patient support improves treatment compliance, minimizes side effects, and fosters informed decisions, including at end of life
  • Expert, peer-to-peer interaction earns cooperation from attending physicians
  • Analytics allow accurate, transparent management of individual and aggregate risk
  • Independence — ITA is not a network, insurer, or pharmaceutical/specialty pharmacy company
  • Member satisfaction increases

The Need for Evidence-Based Intervention

Breast cancer drugs that cost about $2,000 per patient in 1997 today run $90,000 to $210,000 for non-metastatic disease.   Cancer costs a million-member health plan about $280 million a year, of which $35 million to $40 million can be avoided through use of evidence-based treatment.

The difficulties are many:  New cancer care guidelines emerge constantly and average 16 years for widespread adoption.  Complications and side effects spiral unchecked.  Care isn't coordinated.  Patient decisions aren’t always medically sound.  Payers struggle to support overwhelmed members, to identify and manage risk, and to ensure treatment is appropriate.